<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03619265</url>
  </required_header>
  <id_info>
    <org_study_id>NIS114012</org_study_id>
    <nct_id>NCT03619265</nct_id>
  </id_info>
  <brief_title>Evaluation of Activity Levels, Inflammatory Markers, and Overall Wellness.</brief_title>
  <acronym>114-012</acronym>
  <official_title>Evaluation of Activity Levels, Inflammatory Markers, and Overall Wellness. A Randomized, Double-blind, Placebo-controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Natural Immune Systems Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Natural Immune Systems Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose for this protocol is to perform a double-blind, randomized, placebo-controlled,&#xD;
      parallel-arm clinical study in healthy subjects to evaluate the efficacy of a nutraceutical&#xD;
      product on physical and mental energy levels and overall wellness.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2018</start_date>
  <completion_date type="Actual">February 10, 2020</completion_date>
  <primary_completion_date type="Actual">June 25, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A double-blinded, randomized, placebo-controlled, parallel-arm clinical study design will be used.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain level</measure>
    <time_frame>Baseline, 2 weeks, and 8 weeks.</time_frame>
    <description>Pain questionnaire: Scale 0-10, with 0 being pain-free and 10 being the most pain. Change from baseline will be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Range of motion</measure>
    <time_frame>Baseline and 8 weeks.</time_frame>
    <description>Digital inclinometry for measuring mobility of neck, back, hips, knees, and shoulders.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Range of Motion</condition>
  <arm_group>
    <arm_group_label>Prickly pear juice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prickly pear juice, 3 oz daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pear-flavored juice</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pear-flavored juice, 3 oz daily for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prickly pear juice</intervention_name>
    <description>3 ounces daily for 8 weeks.</description>
    <arm_group_label>Prickly pear juice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pear-flavored juice</intervention_name>
    <description>3 ounces daily for 8 weeks.</description>
    <arm_group_label>Pear-flavored juice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults of either gender;&#xD;
&#xD;
          -  35-75 years old;&#xD;
&#xD;
          -  Chronic joint/muscle related pain for at least past 6 months;&#xD;
&#xD;
          -  Body mass index (BMI) at or below 34.9 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bariatric surgery;&#xD;
&#xD;
          -  Diagnosed with diabetes Type I;&#xD;
&#xD;
          -  Taking medication for diabetes Type II;&#xD;
&#xD;
          -  Known serious chronic health condition;&#xD;
&#xD;
          -  Serious active illness within past 12 months;&#xD;
&#xD;
          -  Major surgery within the past 3 months;&#xD;
&#xD;
          -  Major trauma within the past 3 months;&#xD;
&#xD;
          -  Alcohol consumption of more than four standard units/day (for example more than four&#xD;
             regular 12 oz beers (5% alcohol), four small 5-oz glasses of wine (12% alcohol), or&#xD;
             four 1.5 oz shots of 80-proof spirits), or more than 28 units per week;&#xD;
&#xD;
          -  Daily consumption of Nopalea or similar juice products during the past month;&#xD;
&#xD;
          -  Currently taking anti-inflammatory nutritional supplements judged by the study&#xD;
             coordinator to negate or camouflage the effects of the test product;&#xD;
&#xD;
          -  Taking anti-inflammatory medications on a daily basis (81 mg aspirin is acceptable);&#xD;
&#xD;
          -  Use of oral, inhaled or injected steroid medication within the last 6 months (for&#xD;
             example: prednisone, dexamethasone). Nasal sprays for allergies are allowed;&#xD;
&#xD;
          -  Any other significant disease or disorder that the investigator judges may put the&#xD;
             subject at risk because of participation in the study, or may influence the result of&#xD;
             the study;&#xD;
&#xD;
          -  Any other condition or observation that the investigator judges may adversely affect&#xD;
             the person's ability to complete the study;&#xD;
&#xD;
          -  Women of child-bearing potential: Pregnant, breast-feeding, or trying to become&#xD;
             pregnant;&#xD;
&#xD;
          -  Known allergies to ingredients in the test and placebo products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gitte Jensen</last_name>
    <role>Principal Investigator</role>
    <affiliation>NIS Labs</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NIS Labs</name>
      <address>
        <city>Klamath Falls</city>
        <state>Oregon</state>
        <zip>97601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

